A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy

2025-521614-26-00 Protocol D702EC00001 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 Feb 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol D702EC00001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 40
Countries 1
Sites 4

Advanced Solid Tumors

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Feb 2026 → ongoing
Decision date (initial)
2026-01-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-521614-26-00
ClinicalTrials.gov
NCT07161414

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 13 4
Rest of world
United States, United Kingdom, Korea, Republic of
27

Investigational sites

Spain

4 sites · Ongoing, recruiting
Clinica Universidad De Navarra
7001: Oncología, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Clinic De Barcelona
7004: Oncología Médica, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
7002: Oncología, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
7003: Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-02-26 2026-04-01

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-12 Spain Acceptable
2026-01-14
2026-01-15
2 SUBSTANTIAL MODIFICATION SM-1 2026-02-19 Spain Acceptable
2026-03-26
2026-03-30